Asthma Exacerbation and Helium-3 MRI
|ClinicalTrials.gov Identifier: NCT00846014|
Recruitment Status : Withdrawn (Subjects which fit the strict inclusion criteria were not found.)
First Posted : February 18, 2009
Last Update Posted : September 20, 2012
|Condition or disease||Intervention/treatment|
|Asthma Exacerbation||Drug: Helium-3|
Asthma is a pulmonary disorder that affects millions of people each year. The exact method of exacerbation is still under some discussion. Currently there is no cure for the disorder but treatment is of a wide variety.
This study is meant to image the asthmatic lung at various time points post exacerbation. Since pulmonary imaging is currently limited to radiation techniques, this method will allow exacerbated images without the unnecessary exposure to radiation.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Asthma Exacerbation and Helium-3 MRI|
|Study Start Date :||January 2009|
|Primary Completion Date :||August 2011|
|Study Completion Date :||August 2011|
All subjects will be asthmatics that have had an exacerbation (asthma attack) no more than 48 hours before the imaging session.
Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the drug aformoterol will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
Other Name: Hyperpolarized Helium-3
- Image and quantify variation in asthmatic lungs at 0, 6 months, and 12 months [ Time Frame: 1 year ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00846014
|United States, Massachusetts|
|UMASS Medical School Advanced MRI Center|
|Worcester, Massachusetts, United States|
|Principal Investigator:||Mitchell S Albert, Ph.D.||UMASS Medical School|